ORIGINS
Farmatec Laboratories Uruguay began its operations in 1998, maintaining an extensive and respected career within the Uruguayan pharmaceutical industry for over 20 years.
Historically, the company has been dedicated to representing foreign laboratories and assisting them with the importation and commercialization of their medicines in the Uruguayan market.
Its main product is Custodiol, manufactured by the Dr. F. Kohler Chemie GmbH Laboratory in Germany and used primarily for organ transplantation and cardiac surgery. Farmatec Laboratories Uruguay supplies both public and private healthcare providers, remaining as market leader in this segment.
EVOLUTION
Starting in 2018, Farmatec Laboratories Uruguay began Research & Development with a focus on the development of pharmaceutical, cosmetic and veterinary therapeutic products which contain cannabinoids (CBD & THC). In this direction, the company has maintained its historical operations while also researching and developing new lines of products based on these derivatives of the cannabis plant and other natural health ingredients.
Farmatec Laboratories Uruguay possesses authorizations from the Ministry of Public Health (MSP), Ministry of Livestock, Agriculture and Fisheries (MGAP), Institute for the Regulation and Control of Cannabis (IRCCA). It is in compliance with strict regulatory, environmental, operational and safety standards and certifications required in Uruguay by the aforementioned public bodies (GACP/GMP/GLP).
To promote research and scientific development in the fields of human health, cosmetics and veterinary health; generating the next innovations in high quality, safe and effective natural products to satisfy the changing needs of the population.
Laboratorios Farmatec Uruguay is constantly evolving, applying science and technology to create cutting-edge therapeutic solutions of maximum quality and effectiveness.
Farmatec Laboratories Uruguay believes that we are all responsible agents for improving our lives and the lives of others. For this reason, we are carrying out a series of actions that will generate a triple positive impact at an economic, social and environmental level!
Designing, creating and applying innovative processes which allow us to achieve fundamental standards for our operations. We also apply strict internal controls that evaluates and monitor the correct implementation of all actions within our company.
Farmatec Laboratories Uruguay is a company specialized in the development of medical therapies and technologies based on cannabinoids and natural health ingredients. Through an extensive Research & Development program, the company generates transformative results in the fields of human health, cosmetics and veterinary health. We are an agent that generates knowledge, which is transformed into company assets as intellectual property in the form of products, patents, trademarks and / or licenses.
Breadth and diversity in the design of pharmaceutical forms and administration systems, which attend to a variety of clinical conditions with greater efficacy, efficiency and safety.
Participation in the entire R&D spectrum: formulations, pharmacology, toxicology, analytical chemistry, pharmacokinetics and pharmacodynamics, pilot production, stability studies, pharmacotechnical evaluation, approvals for commercialization and patent registration.
Development of human health pharmaceutical products, based on cannabinoids, terpenes, and other complementary natural health ingredients.
Development of cosmetic products, based on cannabinoids, terpenes, and other complementary natural health ingredients.
Development of veterinary products (Dogs, Cats, Equestrian Industry) based on cannabinoids, terpenes, and other complementary natural health ingredients.
General knowledge of the industry, with more than 25 years of experience in the pharmaceutical sector in Uruguay. Likewise, we have studied the regulatory frameworks for cannabis and possess a keen understanding of the legal, normative and regulatory issues related to the cannabis industry.
Farmatec Laboratories Uruguay represents market leading laboratory of Dr. F Kolher Chemie GmbH (Germany), manufacturer of the product Custodiol which is used in organ transplant and cardiac surgery. The company remains as market leader in this segment in Uruguay.
In addition, Farmatec Uruguay is currently under development of its new brands Xaludiol and Xaluvet, products which have been internally developed based on Cannabidiol (CBD) for human and veterinary use respectively.
The company is mainly focused on the areas of Hepatology, Nephrology, Cardiology, Immunology, Neurology and Pain.
Farmatec Laboratories Uruguay has the infrastructure to manufacture pharmaceutical products for human health, cosmetic products and veterinary products, whether they are solid, semi-solid or liquids. In addition, our company is subject to independent third-party analytical testing which permanently monitors and ensures compliance with quality standards and good pharmaceutical manufacturing practices (GAP/GLP/GMP).
Our company has secured a reliable and diversified supply chain of the highest quality raw materials in the market.
Mr. Agustín Vignolo is a successful entrepreneur and executive of multi-disciplinary projects, in the fields of Pharmaceuticals, Nutrition, Agriculture, Information and Communication Technologies.
In 2013, during the genesis of the regulation of the Cannabis Market (Law 19,172) and within the framework of a Public Policy on information and education on Cannabis, Mr. Vignolo co-developed and implemented the Solidarity Energy Project in PPP format. Later, between the years 2017-2019, he held the position of Country Manager for the multinational company Elixinol Global Limited (ASX: EXL), planning and advising on the application of licenses for the development of operations around Cannabis in Uruguay.
Mr. Vignolo currently leads the executive management of Famatec Uruguay S.A.
Mr. Daniel Esteves is an experienced executive with +35 years within the Pharmaceutical Industry in LATAM. He has served, both as a consultant and leader in the implementation of commercial projects, in an extensive list of successful companies in Uruguay and Argentina.
During the years 1987-1997, Mr. Esteves held the position of Commercial Director for Laboratorios Microsules (Uruguay-Argentina), within the Human Division (OTC and Blood Products Line); Food Division; and Generic Products Line.
From 1998 to 2020, Mr. Esteves has led the activities of Farmatec Uruguay S.A. with remarkable solidity, becoming a fundamental piece of the Uruguayan healthcare ecosystem in Cardiology and Transplantation.
Mr. Esteves currently leads the commercial management of Farmatec Uruguay S.A. regionally and globally.
Mr. Martín Azambuja is a Certified Public Accountant (CPA) graduated from the University of the Republic of Uruguay (UDELAR), entrepreneur and athlete, passionate about generating value through high impact projects and companies.
Mr. Azambuja has held leadership positions in multiple companies in Uruguay, demonstrating great capabilities in planning, evaluating and managing inter-disciplinary projects, particularly in the areas of Technology and Communications.
Mr. Azambuja leads the operational area of Farmatec Uruguay S.A., in its current and future evolution, to achieve its goals and objectives in an effective and sustainable way.
Dr. Carlos J. Azambuja has specialized in Molecular Biology in Brazil and at the Curie Institute in Paris, France.
In 1993, Dr. Vet. Azambuja founded Laboratorio GENIA, carrying out activities in human, animal and agricultural genetics; where he currently participates as Chief Executive Officer (CEO).
Mr. Azambuja is an international consulting authority on DNA typing in forensic cases and the identification of individuals, nutrigenetics and genetic medicine, having participated in various renowned local and international congresses.
Dr. Carlos Dau has completed his tertiary studies at the Faculty of Medicine of the University of the Republic of Uruguay (UDELAR), receiving the title of Internist and Hematologist Doctor.
He developed care tasks at Hospital Maciel, Pasteur Hospital, Hospital de Clínicas and at the National Cancer Institute (INCA) where he served as Internist and Chief Hematologist. He worked in private institutions such as CASMU, IMPASA (SMI), Seguro Americano, COMERO, Hospital Italiano, Asociación Español (in the latter as Coordinating Physician and Clinical Hematology Supervisor).
Dr. Dau is a member of the Ethics Committee of INCA, Member of the Uruguayan Society of Hematology (Ex – President) and the Uruguayan Society of Oncology.